NLRP3 and colitis: IL-18 secretion by the NLRP3 inflammasome can indirectly reduce tumor progression in colitis-associated colorectal cancer by inducing regulatory T (Treg) cells to produce IFN-γ and enhancing T-cell and NK-cell cytotoxicity.